Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01933841 · ClinicalTrials.gov registry record

The Impact of Quantitative Neuromuscular Monitoring in the PACU on Residual Blockade and Postoperative Recovery

A clinical trial, sponsored by Vanderbilt University Medical Center.

Completed
Registry status
201
Enrollment target

NCT01933841: Completed study, sponsored by Vanderbilt University Medical Center.

NCT01933841 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 201 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01933841 has completed, sponsored by Vanderbilt University Medical Center.

COMPLETED
Registry status
201 participants
Enrollment target

Study Summary

Neuromuscular blocking drugs (NMBDs) provide anesthesiologists with powerful intraoperative tools, but their use carries the potential risk of serious postoperative complications. NMBD-induced muscle weakness that lingers into the postoperative period, known as postoperative residual curarization (PORC), is present in as many as 40% of all patients that receive neuromuscular blocking agents. The Post Anesthesia Care Unit will be introducing monitoring as part of standard of care. This study will collect data about patients who receive NMBDs and examine the impact of monitoring on incidences of PORC. Our study is designed to test the following hypotheses: Hypothesis 1: The initiation of quantitative TOF monitoring as part of the standard PACU entry evaluation will change practitioner behavior in a manner that decreases the incidence of PORC in surgical patients at VUMC. Hypothesis 2: The initiation of the routine TOF monitoring program will decrease the incidence of short- and long-term postoperative complications at VUMC.

Primary Outcome

This aim will test the hypothesis that initiation of quantitative Train-Of-Four monitoring as part of the standard PACU entry evaluation will change practitioner behavior in a manner that decreases the incidence of PORC in surgical patients at Vanderbilt University Medical Center. Quantitative TOF monitoring will be introduced as a standard component of the PACU entry evaluation for all patients that receive NMBDs as part of their care. It is expected that the proportion of patients with TOF \<

Interventions

  • DEVICE TOF-Watch SX
  • PROCEDURE Notify the provider

Trial Details

FieldValue
Enrollment Target 201 participants
Start Date 2016-08
Est. Completion 2017-07

What the finished NCT01933841 record still lists

NCT01933841 is an observational study that tracks outcomes without assigning an intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 2 interventions - of which TOF-Watch SX is the first listed.

NCT01933841 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01933841 about?

NCT01933841 is a clinical study titled "The Impact of Quantitative Neuromuscular Monitoring in the PACU on Residual Blockade and Postoperative Recovery". Neuromuscular blocking drugs (NMBDs) provide anesthesiologists with powerful intraoperative tools, but their use carries the potential risk of serious postoperative complications. NMBD-induced muscle weakness that lingers into the postoperative period, known as postoperative residual curarization (P...

What is the current status of trial NCT01933841?

This trial is currently completed. The enrollment target is 201 participants. The study started on 2016-08. Estimated completion is 2017-07.

What interventions are being tested in trial NCT01933841?

The interventions under investigation include: TOF-Watch SX (DEVICE), Notify the provider (PROCEDURE).

Who is sponsoring clinical trial NCT01933841?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04422652 · 201 participants · Phase 2

    Combination of Novel Therapies for CKD Comorbid Depression

  • NCT05327114 · 201 participants · Phase 2

    Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • NCT06099769 · 201 participants · Phase 2

    A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

  • NCT06274528 · 201 participants · Phase 2

    DORA and LP in Alzheimer's Disease Biomarkers

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01933841, the US trial registry maintained by the National Library of Medicine. NCT01933841 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.